A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer|Locally Advanced Breast Cancer|Inflammatory Breast Cancer
Interventions: DRUG: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)|DRUG: Pertuzumab IV|DRUG: Trastuzumab IV|DRUG: Trastuzumab Emtansine|DRUG: Investigator's Choice of Chemotherapy|PROCEDURE: Surgery|RADIATION: Radiotherapy
Sponsor: Hoffmann-La Roche